, and NO 2 − is incompletely understood. Ghosh et al 2 reported that erythrocytic xanthine oxidoreductase (XOR) plays a crucial role in lowering blood pressure in hypertensives on oral administration of NO 3 − by reducing NO 3 − -derived NO 2 − to NO. But because NO 2 − reduction to NO by XOR requires anaerobic conditions, XOR is unlikely to generate NO from NO 2 − in erythrocytes. Allopurinol is frequently used to support XOR involvement in various processes. Yet, the action of allopurinol is not restricted to XOR. Allopurinol decreases significantly the concentration of circulating asymmetrical dimethylarginine (ADMA), 3 an endogenous inhibitor of NO synthase. Thus, allopurinol may normalize endothelial dysfunction 4 by abolishing the inhibitory action of ADMA on NO synthase activity. Reduction of oxidative stress by allopurinol has been proposed as a mechanism explaining the decrease of circulating ADMA seen on allopurinol administration. 3 Yet, allantoin is not a reliable oxidative stress biomarker, because allopurinol inhibits XORinduced formation of uric acid, 5 the precursor of allantoin. In plasma and urine of patients with peripheral arterial occlusive disease, we did not find any correlation between ADMA and the oxidative stress biomarkers malondialdehyde and 15(S)-8-iso-prostaglandin F 2α (Figure) . This suggests that allopurinol is unlikely to reduce circulating ADMA concentration by decreasing oxidative stress. Relationship between malondialdehyde (MDA) or 15(S)-8-iso-prostaglandin F 2α (15(S)-8-iso-PGF 2α ) and asymmetrical dimethylarginine (ADMA) in plasma (A) and between 15(S)-8-iso-PGF 2α and ADMA in urine (B) of 40 patients with peripheral arterial occlusive disease. MDA, 15(S)-8-iso-PGF 2α , and ADMA were measured by GC-MS/MS (gas chromatography-mass spectrometry-mass spectrometry).
